EP 2104R

Drug Profile

EP 2104R

Latest Information Update: 22 Apr 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dyax; EPIX Pharmaceuticals
  • Developer EPIX Pharmaceuticals
  • Class Contrast media; Lanthanoid series elements; Peptides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 20 Apr 2010 Intellectual properties pertaining to EP 2104R are being auctioned in the US (http://www.finnwarnkegayton.com)
  • 07 Dec 2006 Final results from a phase IIA clinical trial in Magnetic resonance imaging added to the Diagnostic Agents therapeutic trials section
  • 18 Jul 2006 EP 2104R is available for licensing worldwide (http://www.epixpharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top